title: Trends in the use of evidence-based therapy for resectable gastric cancer.
abstract: OBJECTIVE
  Two pivotal randomized controlled trials (RCTs), the Intergroup (INT-0116) and Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) trials, demonstrated a survival benefit of multimodality therapy in patients with resectable gastric cancer. The purpose of this study was to determine utilization rates of these treatment regimens in the United States and to identify factors associated with receipt of evidence-based care.
  
  
  METHODS
  We performed a retrospective cohort study of patients with Stage IB-IV (M0) gastric adenocarcinoma who underwent resection from 1991 to 2009 using the linked SEER-Medicare database.
  
  
  RESULTS
  Only 19.1% of patients received post-operative chemoradiation therapy (CRT), and 1.9% received peri-operative chemotherapy; most patients underwent surgery alone (60.9%). Patients with more advanced stage, younger age, and fewer comorbidities were more likely to receive evidence-based care. We found no association between National Cancer Institute (NCI) designation and delivery of multimodality therapy. However, patients who underwent medical oncology consultation were much more likely to receive evidence-based treatment (OR 3.10, 95% CI 2.35-4.09).
  
  
  CONCLUSIONS
  Rates of peri-operative chemotherapy and post-operative CRT in patients with resected gastric cancer remain remarkably low, despite high-quality RCT evidence demonstrating their benefit. Furthermore, NCI designation does not appear to be associated with administration of evidence-based treatment.
authors.affiliation: Department of Surgery, Vanderbilt Medical Center, Nashville, Tennessee.
authors.forename: Rebecca A
authors.initials: RA
authors.lastname: Snyder
authors.forename: David F
authors.initials: DF
authors.lastname: Penson
authors.forename: Shenghua
authors.initials: S
authors.lastname: Ni
authors.forename: Tatsuki
authors.initials: T
authors.lastname: Koyama
authors.forename: Nipun B
authors.initials: NB
authors.lastname: Merchant
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology / Q000628:therapy; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D059186:Chemoradiotherapy, Adjuvant / Q000706:statistics & numerical data*; D017024:Chemotherapy, Adjuvant / Q000706:statistics & numerical data; D015331:Cohort Studies; D015897:Comorbidity; D019317:Evidence-Based Medicine; D005260:Female; D005743:Gastrectomy; D006801:Humans; D008297:Male; D015999:Multivariate Analysis; D009367:Neoplasm Staging; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data*; D016032:Randomized Controlled Trials as Topic; D012017:Referral and Consultation / Q000706:statistics & numerical data; D012189:Retrospective Studies; D018426:SEER Program; D013274:Stomach Neoplasms / Q000473:pathology / Q000628:therapy*; D014481:United States / Q000453:epidemiology
chemical_list: D000970:Antineoplastic Agents
keywords: chemoradiotherapy, adjuvant; chemotherapy, adjuvant; epidemiology; stomach neoplasms